CAMBRIDGE, Mass., Nov. 22 /PRNewswire/ -- Xanthus Life Sciences, Inc., a
privately-held oncology drug development company, today announced that Richard
T. Dean, Ph.D., President and CEO of Xanthus, will present a company overview
and update at the Lazard Capital Markets Life Sciences Conference. The
presentation is scheduled for Wednesday, November 30, 2005 at 3:00 pm at The
New York Palace Hotel. A live audio webcast of the presentation will be
available on the Company's website located at http://www.xanthus.com. A
replay of the presentation will be posted on the Xanthus website approximately
thirty minutes after the event.
About Xanthus Life Sciences, Inc.
Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical-
stage, small-molecule oncology candidates through a management team whose
accomplished track record encompasses all aspects of drug development, from
discovery through regulatory approval and commercialization. The Company is
applying its expertise both to advance its current pipeline and expand it into
indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson,
MacDougall Biomedical Communications, Inc. --
kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr.,
Senior Vice President and Chief Financial Officer,
Xanthus Life Sciences, Inc. -- (617) 225-0522 x125
SOURCE Xanthus Life Sciences, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or
John A. McCarthy, Jr., Senior Vice President and Chief Financial
Officer of Xanthus Life Sciences, Inc., +1-617-225-0522 ext. 125
|
